Cargando…

Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes

Hypertension in the elderly is one of the main risk factors of cardiovascular and cerebrovascular diseases. Knowledge regarding the mechanisms of hypertension and specific considerations in managing hypertensive elderly through pharmacological intervention(s) is fundamental to improving clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tadevosyan, Artavazd, MacLaughlin, Eric J, Karamyan, Vardan T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417921/ https://www.ncbi.nlm.nih.gov/pubmed/22915967 http://dx.doi.org/10.2147/PROM.S8384

Ejemplares similares

Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor
por: Zhang, Yong, et al.
Publicado: (2022)

Intracellular Angiotensin‐II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion
por: Tadevosyan, Artavazd, et al.
Publicado: (2017)

Distribution of a novel binding site for angiotensins II and III in mouse tissues
por: Rabey, Felicia M., et al.
Publicado: (2010)

Enzymatic pathways of the brain renin–angiotensin system: Unsolved problems and continuing challenges
por: Karamyan, Vardan T., et al.
Publicado: (2007)

Eprosartan mesylate, an angiotensin II receptor antagonist
por: Qian, Jing-Jing, et al.
Publicado: (2011)

Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension
por: Wensing, Georg, et al.
Publicado: (2007)

Spectrofluorimetric method for determination of some angiotensin II receptor antagonists
por: El-Shaboury, Salwa R., et al.
Publicado: (2012)

Angiotensin II receptor antagonists a potential therapy for SARS
Publicado: (2013)

The Patient and His Doctor
por: MacLaughlin, F. A.
Publicado: (1948)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension
por: AlSiraj, Yasir, et al.
Publicado: (2021)

Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats
por: Choopani, Samira, et al.
Publicado: (2022)

Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome
por: Haaland, Kirsti
Publicado: (2010)

Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure
por: Wegleiter, K., et al.
Publicado: (2018)

Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks
por: Kario, K, et al.
Publicado: (2013)

Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor
por: Cha, Seung Ah, et al.
Publicado: (2018)

Combination therapy with an angiotensin‐converting‐enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy
por: Nakamura, Akihiko, et al.
Publicado: (2012)

Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists
por: Lallemant, Marine, et al.
Publicado: (2018)

Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice
por: Waseda, Yuko, et al.
Publicado: (2008)

Effect of Angiotensin II Type 1 Receptor Antagonist, Losartan on Inflammatory Factor in Atherosclerotic Rabbits
por: Xu, Yan-min, et al.
Publicado: (2013)

The role of peptidase neurolysin in neuroprotection and neural repair after stroke
por: Karamyan, Vardan T.
Publicado: (2020)

Between two storms, vasoactive peptides or bradykinin underlie severity of COVID‐19?
por: Karamyan, Vardan T.
Publicado: (2021)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021)

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
por: Quan, Hailian, et al.
Publicado: (2020)

Influence of Angiotensin II Subtype 2 Receptor (AT(2)R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT(1)R) Blockade
por: Jones, Emma S., et al.
Publicado: (2012)

Differential brain angiotensin-II type I receptor expression in hypertensive rats
por: Braga, Valdir A.
Publicado: (2011)

Angiotensin II Modulates Calcium/Phosphate Excretion in Experimental Model of Hypertension: Focus on Bone
por: Castoldi, Giovanna, et al.
Publicado: (2022)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Reciprocal Roles of Angiotensin II and Angiotensin II Receptors Blockade (ARB) in Regulating Cbfa1/RANKL via cAMP Signaling Pathway: Possible Mechanism for Hypertension-Related Osteoporosis and Antagonistic Effect of ARB on Hypertension-Related Osteoporosis
por: Guan, Xiao-Xu, et al.
Publicado: (2011)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Deletion of the angiotensin II type 1 receptor–associated protein enhances renal sodium reabsorption and exacerbates angiotensin II–mediated hypertension
por: Ohsawa, Masato, et al.
Publicado: (2014)

Dual deficiency of angiotensin‐converting enzyme‐2 and Mas receptor enhances angiotensin II‐induced hypertension and hypertensive nephropathy
por: Ni, Jun, et al.
Publicado: (2020)

Distribution of Non-AT(1), Non-AT(2) Binding of (125)I-Sarcosine(1), Isoleucine(8) Angiotensin II in Neurolysin Knockout Mouse Brains
por: Speth, Robert C., et al.
Publicado: (2014)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
por: Li, Mingfei, et al.
Publicado: (2021)

Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19
por: Abedtash, Amirhossein, et al.
Publicado: (2021)

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome
por: Palazzuoli, Alberto, et al.
Publicado: (2020)

Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms
por: Lamblin, Nicolas, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_9r4pnjme58cre6km9k20sr1q20